Executive record

Tiago Girao

Public governance roles and source-backed Claims for this individual.

Follow
More
Challenge a Claim

Alpha ID: alpha:person:tiago-girao-imvtVersion: public-0As of: 2026-09-30

Not yet claimed8 published Claims2 sources

Key Claims

Biography

Mr. Girao has served as Chief Financial Officer since April 2025, previously serving as CFO for several Roivant subsidiaries and as CFO of Cytory Therapeutics. He began his career in audit at Ernst & Young and KPMG and holds a CPA license in California.

Alpha editorial summary written from the cited sources below. It does not change any Claim on this record.

Executive career

  1. 2025 to end not publishedExecutive title: Chief Financial Officer · Organization not publishedIMVT DEF 14A executive officers

Claims

Conflicts and accountability

Alpha has not published independence, related-party, proceedings or disciplinary Claims for this record. This is not a finding that none exist.

Only disclosed facts and public registers appear here. Executive records carry no credit, personal litigation, background screening or underwriting views. None observed is not a clearance.

Evidence, history and coverage

Additional published Claims

Published evidence records

2 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.

  1. IMVT DEF 14A executive officers

    sec filing · Source published: Jul 9, 2025 · Retrieved: May 15, 2026

    Supports 5 claims
    • AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 15, 2026
    • Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 15, 2026
    • Executive company: Executive at Immunovant Inc · Claim reviewed: May 15, 2026
    • Executive title: Executive title: Chief Financial Officer · Claim reviewed: May 15, 2026
    • Technology background: Technology background: not identified in the cited filing · Claim reviewed: May 15, 2026

  2. IMVT executive roster source

    sec filing · Source published: Date unavailable · Retrieved: May 3, 2026

    Supports 5 claims
    • AI expertise: AI expertise: not identified in the cited filing · Claim reviewed: May 3, 2026
    • AI governance relevance: AI governance relevance: not identified in the cited filing · Claim reviewed: May 3, 2026
    • Executive company: Executive at Immunovant Inc · Claim reviewed: May 15, 2026
    • Executive function: Finance Controls (CFO) · Claim reviewed: May 3, 2026
    • Executive title: Executive title: Chief Financial Officer · Claim reviewed: May 15, 2026